Suppr超能文献

东南亚及太平洋地区用于治疗新生儿和儿童严重细菌感染的经验性抗生素治疗方案中的覆盖缺口。

Coverage gaps in empiric antibiotic regimens used to treat serious bacterial infections in neonates and children in Southeast Asia and the Pacific.

作者信息

Williams Phoebe C M, Jones Mark, Snelling Thomas L, Duguid Robert, Moore Nerida, Dickson Benjamin, Wu Yue, Saunders Jessica, Wijeratne Priyali, Douangnouvong Anousone, Ashley Elizabeth A, Turner Paul

机构信息

Faculty of Medicine, School of Public Health, The University of Sydney, Sydney, NSW, Australia.

Department of Infectious Diseases, Sydney Children's Hospital Network, Sydney, NSW, Australia.

出版信息

Lancet Reg Health Southeast Asia. 2023 Oct 31;22:100291. doi: 10.1016/j.lansea.2023.100291. eCollection 2024 Mar.

Abstract

BACKGROUND

High levels of antimicrobial resistance (AMR) are propagating deaths due to neonatal and paediatric infections globally. This is of particular concern in Southeast Asia and the Pacific, where healthcare resources are constrained and access to newer agents to treat multidrug-resistant pathogens is limited.

METHODS

To assess the coverage provided by commonly prescribed empiric antibiotic regimens for children in low- and middle-income countries in Southeast Asia and the Pacific, we built a weighted incidence syndromic combination antibiogram (WISCA), parameterised using data obtained from a systematic review of published literature incorporating WHO-defined SEARO and WPRO regions in Ovid MEDLINE, EMBASE, Global Health and PubMed. Susceptibility data for bacterial pathogens were extracted to provide coverage estimates for pre-specified antibiotics (aminopenicillins, gentamicin, third-generation cephalosporins and carbapenems), reported at the regional level.

FINDINGS

6648 bacterial isolates from 11 countries across 86 papers were included in the Bayesian WISCA model, which weighted bacterial incidence and antimicrobial susceptibility of relevant isolates. Coverage provided by aminopenicillins in neonatal sepsis/meningitis was 26% (80% credible interval: 16-49) whilst gentamicin coverage was 45% (29-62). Third-generation cephalosporin coverage was only 29% (16-49) in neonatal sepsis/meningitis, 51% (38-64) in paediatric sepsis and 65% (51-77) in paediatric meningitis. Carbapenems were estimated to provide the highest coverage: 81% (65-90) in neonatal sepsis/meningitis, 83% (72-90) in paediatric sepsis and 79% (62-91) in paediatric meningitis.

INTERPRETATION

These findings reveal alarmingly high rates of resistance to commonly prescribed empirical therapies for neonatal and paediatric sepsis and meningitis in the Asia-Pacific region.

FUNDING

This research was funded in whole, or in part, by the Wellcome Trust [220211]. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. PCMW is supported by a National Health and Medical Research Council (NHMRC) Investigator Grant. NHMRC had no involvement in the design or conduct of the research.

摘要

背景

全球范围内,高水平的抗菌药物耐药性(AMR)正在导致新生儿和儿童感染相关死亡人数不断增加。在东南亚和太平洋地区,这一问题尤为令人担忧,因为该地区医疗资源有限,获取治疗多重耐药病原体的新型药物的机会也很受限。

方法

为评估东南亚和太平洋地区低收入和中等收入国家儿童常用经验性抗生素治疗方案的覆盖范围,我们构建了一个加权发病率综合征组合抗菌谱(WISCA),使用从对已发表文献的系统评价中获得的数据进行参数化,这些文献纳入了Ovid MEDLINE、EMBASE、Global Health和PubMed中世界卫生组织定义的东南亚区域办事处(SEARO)和西太平洋区域办事处(WPRO)地区。提取细菌病原体的药敏数据,以提供区域层面报告的预先指定抗生素(氨基青霉素、庆大霉素、第三代头孢菌素和碳青霉烯类)的覆盖范围估计值。

研究结果

贝叶斯WISCA模型纳入了86篇论文中来自11个国家的6648株细菌分离株,该模型对相关分离株的细菌发病率和抗菌药敏性进行了加权。氨基青霉素在新生儿败血症/脑膜炎中的覆盖范围为26%(80%可信区间:16 - 49),而庆大霉素的覆盖范围为45%(29 - 62)。第三代头孢菌素在新生儿败血症/脑膜炎中的覆盖范围仅为29%(16 - 49),在儿童败血症中为51%(38 - 64),在儿童脑膜炎中为65%(51 - 77)。据估计,碳青霉烯类提供的覆盖范围最高:在新生儿败血症/脑膜炎中为81%(65 - 90),在儿童败血症中为83%(72 - 90),在儿童脑膜炎中为79%(62 -

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1290/10934317/3bf65be71e9b/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验